

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Serum hepcidin and iron status parameters in pregnant women and the association with adverse maternal and foetal outcome: a study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032280
Article Type:	Protocol
Date Submitted by the Author:	11-Jun-2019
Complete List of Authors:	Amstad Bencaiova, Gabriela; University Hospital Basel, Department of Obstetrics; Vogt, Deborah; University of Basel, Clinical Trial Unit Hoesli, Irene; University Hospital, University Basel, Obstetrics
Keywords:	hepcidin, pregnancy, BMI, pregnancy outcome

SCHOLARONE™  
Manuscripts

1  
2  
3 **Serum hepcidin and iron status parameters in pregnant**  
4 **women and the association with adverse maternal and**  
5 **foetal outcome: a study protocol**  
6  
7  
8  
9  
10  
11  
12  
13

14 **G Amstad Bencaiova, D R Vogt, I Hoesli**

15  
16  
17  
18 Department of Obstetrics and Antenatal Care, University Hospital Basel,  
19  
20 University Basel, Switzerland  
21  
22

23  
24 Clinical Trial Unit, Department of Clinical Research, University Hospital Basel  
25  
26 and University of Basel  
27  
28

29  
30 **Corresponding author:** Gabriela Amstad, MD  
31

32  
33  
34 Department of Obstetrics and Antenatal Care,  
35

36  
37 University Hospital of Basel  
38

39  
40 Spitalstrasse 21  
41

42  
43 CH-4031 Basel  
44

45  
46 Switzerland  
47  
48

49  
50  
51 Email: [gabriela.amstad@usb.ch](mailto:gabriela.amstad@usb.ch)  
52

53  
54  
55 Phone +41 61 556 59 22  
56

57  
58 Fax +41 61 265 9198  
59  
60

## Abstract

**Introduction:** Hepcidin production is normally upregulated by iron stores, and in obesity has been shown to be overexpressed and correlated with low iron status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of ferroportin, which probably associates with the development of diabetes complication. Firstly, we investigate the difference of serum hepcidin and iron parameters between obese and non-obese pregnant women; secondly, we examine the correlation between serum hepcidin and adverse maternal and neonatal outcomes in pregnant women.

**Methods and analysis:** This is a mono-centre, observational study with a study (obese) and a control group (non-obese women). 188 singleton pregnancies will be recruited in the first trimester. Thereof, we expect 75 with a BMI  $\geq 30$  kg/m<sup>2</sup> and 113 with a BMI 18.5 -- 30 kg/m<sup>2</sup>. Serum hepcidin, iron and haematological parameters will be measured at 11-14, 24-28, 32-36 weeks of gestation and at time of delivery. Blood pressure, weight, BMI and smoking status will be examined at all visits. We will assess the composite endpoints adverse maternal outcome (including pre-eclampsia, gestational hypertension, gestational diabetes, haemorrhage, placenta abruption), and adverse neonatal outcome (preterm birth, intrauterine growth restriction, preterm premature rupture of membranes, Apgar score <7 at 5 minutes, still birth, neonatal death).

Recruitment has started in April 2019.

1  
2  
3  
4  
5  
6  
7 **Ethics and dissemination:** This study received ethical approval from the ethics  
8  
9 committee in Basel. It was registered under <http://www.ClinicalTrials.gov>  
10  
11 (NCT03792464) on 7 January 2019.  
12  
13

14  
15 **Trial registration number:** NCT03792464.  
16  
17

### 18 19 **Strengths and limitations of this study**

20  
21

22  
23 This is a prospective study to examine the difference of serum hepcidin and iron  
24  
25 parameters between obese and non-obese pregnant women.  
26  
27

28  
29 For the first time to our knowledge, a prospective study will be performed in  
30  
31 order to verify the association between hepcidin and pregnancy outcome.  
32  
33

34  
35 At the time of planning this study, to our knowledge, no data on hepcidin  
36  
37 levels of obese pregnant women in the first trimester were available. Hepcidin  
38  
39 levels in our study might thus deviate from our assumptions for sample size  
40  
41 estimation. Therefore, we will perform a blinded sample size re-estimation.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Obesity is the most common problem in obstetrics that affects both the mother and her offspring.<sup>1</sup> Obesity causes short term and long term problems for the mother, such as increasing her risk of gestational diabetes (GDM) and pre-eclampsia during pregnancy and further increases the risk of developing the metabolic syndrome in later life. The offspring have an increased risk of obstetric morbidity and mortality and, consistent with the developmental origins of health and disease, a long term risk of childhood obesity and metabolic dysfunction.<sup>1</sup>

Obesity is also associated with an increased risk of iron deficiency, attributable to adiposity-related inflammatory mediators on iron regulatory pathways.<sup>2</sup> The pro-inflammatory cytokine interleukin-6 (IL-6), frequently elevated in obesity, has been shown to induce expression of hepcidin<sup>2</sup>, a negative regulator of intestinal iron absorption and macrophage iron efflux. Normal foetal growth and development is dependent upon maternal iron sufficiency during pregnancy. Pregnant women have an increased requirement of iron to support foetoplacental development, expansion of maternal red blood cell mass, and to compensate for intrapartum blood loss; to meet this need, absorption of dietary iron is enhanced concomitant with increased utilization of existing iron stores. During a healthy pregnancy, hepcidin is reduced, enabling iron transfer to the fetus.<sup>3-6</sup> Obesity in

1  
2  
3 pregnancy may lead to hepcidin excess and decreased iron transfer to the fetus.<sup>7-</sup>  
4

5  
6 <sup>9</sup> Low iron stores are reported to be more common in obese pregnant women.<sup>10</sup>  
7

8  
9 The correlation between serum ferritin and hepcidin has been shown in previous  
10  
11 studies.<sup>3,5,8,11,12</sup> Although in other studies, no correlation between serum hepcidin  
12  
13 and iron status has been found.<sup>4,6,13</sup> To strengthen the link between the poor iron  
14  
15 status of obesity and hepcidin, there is the interesting observation that hepcidin  
16  
17 is expressed not only in the liver but also in adipose tissue and that mRNA  
18  
19 expression is increased in adipose tissue of obese pregnant patients.<sup>7</sup> The  
20  
21 increased hepcidin may restrain the iron release from the cells by affecting the  
22  
23 expression of ferroportin, which probably associates with the development of  
24  
25 diabetes complication.<sup>14</sup> Iron content appears to be increased in the  
26  
27 subcutaneous and visceral adipose tissue of obese patients, and negatively  
28  
29 correlated with adiponectin expression, which could be contributing to insulin  
30  
31 resistance and the metabolic complications of obesity.<sup>15</sup>  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 There are few studies examining the influence of maternal obesity on maternal  
42  
43 iron status, with some indicating that iron status may be compromised <sup>(7-9,16)</sup>, and  
44  
45 others reporting no impact.<sup>17</sup> However dietary or iron supplementation was not  
46  
47 assessed and might be responsible for divergent results. There is no study  
48  
49 evaluating the difference of serum hepcidin and ferritin between obese and non-  
50  
51 obese pregnant women longitudinally during pregnancy as well as the  
52  
53 association between these parameters and adverse pregnancy outcome.  
54  
55  
56  
57  
58  
59  
60

## Methods and analysis

### Primary objective

The primary endpoint is serum hepcidin level (ng/ml) measured at 11-14 weeks of gestation.

### Secondary objectives

1. To compare iron status parameters, haemogram and CRP measured in the first trimester between obese and non-obese pregnant women.
2. To describe the course of serum hepcidin, iron status parameters, haemogram, CRP, weight and BMI during pregnancy and to compare them between obese and non-obese pregnant women.
3. To describe the correlations between serum hepcidin, iron status parameters, haemogram, CRP, weight and BMI in each trimester and at delivery.
4. To investigate whether adverse pregnancy outcome is associated with serum hepcidin and iron status in the first trimester and during total pregnancy.
5. To investigate whether adverse neonatal outcome is associated with serum hepcidin and iron status in the first trimester and during total pregnancy.

### Study design

This is a mono-centre, observational study with a study (obese) and a control group (non-obese women). This study protocol was developed on the basis of



1  
2  
3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT;  
4  
5 see online SPIRIT checklist for further details).  
6  
7  
8  
9  
10

## 11 **Study settings**

12  
13  
14  
15 The study will be conducted at the University Hospital of Basel, Department of  
16  
17 Obstetrics and Antenatal Care with 2800 deliveries/year. The study has started  
18  
19 in April 2019. We estimate to recruit all patients within 18 months. A total of  
20  
21 N=188 healthy pregnant women (expected 75=40% with BMI  $\geq$  30 kg/m<sup>2</sup>) will  
22  
23 be recruited in the first trimester in our outpatients' department. Considering a  
24  
25 drop-out rate of 10% we will have a total of 169 evaluable women.  
26  
27  
28  
29  
30  
31  
32  
33  
34

## 35 **Eligible criteria**

### 36 Inclusion criteria

- 37
- 38
- 39
- 40
- 41 • Age  $\geq$  18 years
- 42
- 43
- 44 • Singleton pregnancy
- 45
- 46
- 47 • BMI  $\geq$  18.5 kg/m<sup>2</sup>
- 48
- 49
- 50 • Gestational age at recruitment: 11-14 of gestational weeks
- 51
- 52
- 53 • Written informed consent.
- 54
- 55

### 56 Exclusion criteria

57  
58  
59  
60

- Foetal genetic, chromosomal or intervention-requiring morphological abnormalities
- Chronic disease of heart, liver, kidney, cardiovascular system, gastrointestinal tract, neurologic, autoimmune, haematological disorders and psychiatric disorders or known infection like hepatitis or HIV
- The inability to read and/or understand the participant's information sheet.

### **Assessment of primary outcome**

The serum hepcidin will be investigated at 11-14, 24-28, 32-36 weeks of gestation and at labour. Blood samples are collected by venepuncture. The measurement of serum hepcidin will be conducted at the University Hospital of Basel, Department of Biomedicine. Serum hepcidin will be measured with an ELISA. No additional visit is necessary besides the standard routine antenatal care visits.

### **Assessment of secondary outcomes**

Serum iron parameters (serum ferritin and soluble transferrin receptors) will be measured at 11-14, 24-28, 32-36 weeks of gestation and at labour. Iron parameters will be determined using routine laboratory methodology. Blood samples will be collected by venepuncture. All blood measurements will be

1  
2  
3 conducted at the University Hospital of Basel, Department of Laboratory  
4  
5  
6 Medicine and Department of Biomedicine.  
7

8  
9 The following maternal outcome will be investigated: pre-eclampsia defined  
10  
11 according to the «Report of the American College of Obstetricians and  
12  
13 Gynecologists` Task Force on Hypertension in pregnancy»<sup>18</sup>, pregnancy induced  
14  
15 hypertension<sup>18</sup>, infection in pregnancy (urinary tract infection, vaginal infection,  
16  
17 chorioamnionitis etc.), anaemia and iron deficiency in pregnancy according to  
18  
19 the World Health Organization (WHO) with ferritin cut-off of 15 µg/l<sup>19</sup>,  
20  
21 cholestasis of pregnancy, gestational diabetes mellitus according to the results of  
22  
23 an oral 75g glucose test, mode of delivery, abnormal placentation, placental  
24  
25 abruption, thromboembolism in pregnancy and puerperium, peripartum and  
26  
27 postpartum haemorrhage, estimated blood loss, anaemia in postpartum,  
28  
29 puerperal infection or sepsis, transfusion requirement. Pre-eclampsia, gestational  
30  
31 hypertension, GDM, cholestasis of pregnancy, peripartal haemorrhage  
32  
33 (increased blood loss peripartal or significant haemoglobin- difference between  
34  
35 before and after delivery > 30 g/l), infections, anaemia and placenta abruption  
36  
37 are defined as adverse maternal outcome.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 The following neonatal outcome should be investigated: gestational age at birth,  
50  
51 birth weight, Apgar score, pH levels, preterm delivery < 37 weeks of gestation,  
52  
53 preterm premature rupture of membranes (PPROM), macrosomia with birth  
54  
55 weight above 95th percentile, intrauterine growth restriction (IUGR) with birth  
56  
57 weight below 5th percentile, low birth weight (LBW) with birth weight below  
58  
59  
60

1  
2  
3 2500 g, still birth defined according to WHO<sup>20</sup>, neonatal death defined according  
4  
5  
6 to UNICEF and WHO<sup>21</sup>, admissions to the neonatal unit care (NICU). Preterm  
7  
8 birth, IUGR, PPRM, macrosomia, Apgar score < 7 at 5, still birth and neonatal  
9  
10 death are defined as adverse neonatal outcome  
11  
12  
13  
14  
15  
16

### 17 **Participant time line and study procedures**

18  
19  
20 All healthy pregnant patients with regular care at our outpatients' department are  
21  
22 counselled and asked at six –10 weeks of gestation to participate. At 10+0 to  
23  
24 13+6 weeks of gestation, all women have to undergo a first trimester ultrasound  
25  
26 scan which is standard care. The ultrasound scan is used to confirm gestational  
27  
28 age, diagnose any major foetal abnormalities. All pregnant women that meet in-  
29  
30 /exclusion criteria will be recruited in the first trimester in the framework of  
31  
32 regular pregnancy visit through physicians, midwives and study coordinators.  
33  
34  
35 Serum hepcidin, iron and haematological parameters will be measured at 11-14,  
36  
37 24-28, 32-36 weeks of gestation and at labour. The blood pressure, weight,  
38  
39 weight gain, body mass index (BMI) and smoking status will be examined at all  
40  
41 visits as a standard of care. Time and event schedule provides an overview about  
42  
43 the schedule of observations and assessments (Table 1).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

### 56 **Haematological parameters**

57  
58  
59  
60

1  
2  
3 This is a routine examination on the visit 1, 2, 3 and 4 haemoglobin (Hb), red  
4  
5 blood cell count (RBC), haematocrit (HCT), mean corpuscular volume (MCV),  
6  
7 mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin  
8  
9 concentration (MCHC), percentage of microcytic erythrocytes (MRC),  
10  
11 hypochromic red blood cells (HRC) and reticulocyte haemoglobin content (CHr)  
12  
13 are measured using a haematology analyser. Mean corpuscular haemoglobin is  
14  
15 automatically calculated from Hb and RBC.  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Serum ferritin, CRP, hepcidin and soluble transferrin receptors**

26  
27  
28 There are additional examinations on the visit 1, 2, 3 and 4. Ferritin is assessed  
29  
30 by chemiluminescence immunoassay and CRP is assessed by  
31  
32 immunoturbidimetry. Soluble transferrin receptors and serum hepcidin are  
33  
34 measured with an ELISA.  
35  
36  
37  
38  
39  
40  
41

### 42 **Recording of medications**

43  
44 All medications being continued by a patient on enrolment and all medications  
45  
46 given in addition must be documented on the Case report form (CRF) and in the  
47  
48 patient's medical records.  
49  
50  
51

### 52 **Sample size**

1  
2  
3 Sample size is estimated so that a difference between obese and non-obese  
4 pregnant women regarding the primary endpoint- serum hepcidin level in the  
5 first trimester- can be shown with 80% power, at a significance level  $\alpha = 5\%$ .  
6  
7  
8  
9

10 Sample size estimation is based on the following assumptions:

- 11 • The proportion of obese women is expected to be 40%.
- 12 • We assume hepcidin levels to be normally distributed with equal variance for  
13 obese and non-obese women.
- 14 • Based on results reported in Dao et al.<sup>9</sup> for obese women in the second  
15 trimester, and assuming these are similar in the first trimester, we assume a  
16 mean hepcidin level of 13.5 ng/ml in the first trimester and a standard deviation  
17 of  $\sigma = 9.0$  ng/ml. Dao et al.<sup>9</sup> report a mean difference of 8.0 ng/ml between  
18 obese and non-obese women, while Garcia-Valdes et al.<sup>7</sup> report a mean  
19 difference of approximately 5.0 ng/ml. Here, we aim to show a clinically  
20 relevant difference of 4.0 ng/ml, thus we assume  $\mu = 17.5$  ng/ml in non-obese  
21 women.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Sample size was calculated using a re-sampling procedure. Each sample size  
46 ( $n_i=1, \dots, 71 = 20, \dots, 300$ ) was evaluated first determining the number of obese  
47 women (expected 40%, c.f. above) by sampling 999 times from a binomial  
48 distribution with  $n = n_i$  and probability  $p = 0.4$ . Then, 999 times  $n_i$  observations,  
49 were sampled from the above described distributions for non-obese women and  
50 obese women, respectively. The difference in each sample between obese and  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 non-obese women was then tested using a two- samples t-test. The null  
4  
5 hypothesis was rejected when the difference was statistically significant ( $p <$   
6  
7  $0.05$ ). Sample size was set to ensure a significant result in at least 80 % of the  
8  
9 cases (power:  $1 - \beta = 0.8$ ), at a significance level  $\alpha = 5 \%$ .

10  
11  
12  
13  
14 Supposing to show a hepcidin difference of 4.0 ng/ml, a total of 188 women  
15  
16 should be recruited in order to have a total of 169 evaluable women, considering  
17  
18 a drop-out rate of 10%. A sample size re-estimation is planned as soon as  
19  
20 hepcidin levels of the first trimester of 80% of the initially estimated number of  
21  
22 women (i.e. 136 out of 169) will be available (c.f. Interim Analysis).  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Data collection**

32  
33  
34 The study data recorded in the CRF will be transferred to a corresponding  
35  
36 electronic CRF (e-CRF) by a designated person. The principal investigator will  
37  
38 be responsible for assuring that the data entered into the e-CRF is complete,  
39  
40 accurate, and that the entry and updates are performed in timely manner. All  
41  
42 information recorded in the e-CRFs will be traceable to the source documents in  
43  
44 the patient's file and in the date source files.  
45  
46  
47  
48  
49

50  
51 The e-CRF will be implemented by the Data management group at the Clinical  
52  
53 Trial Unit Basel using the electronic data capture (EDC) software SecuTrial.  
54  
55 The EDC system runs on a server maintained by the IT-department of the  
56  
57 University Hospital Basel.  
58  
59  
60

1  
2  
3 Internal data management will be conducted. The data-review and data-handling  
4 documents, to be developed during the initiation phase of the study, will include  
5 specifications for consistency and plausibility checks on data and will also  
6 include data handling rules for obvious data errors.  
7  
8  
9  
10  
11  
12

13  
14 In compliance with the International Council on Harmonization and GCP  
15 guidelines the investigator/institution will maintain all source documents that  
16 support the data collected from each patient, and all documents as specified in  
17 Essential Documents for the Conduct of a study and as specified by the  
18 applicable regulatory requirements. The investigator/institution will take  
19 measures to prevent accidental or premature destruction of these documents.  
20 Essential documents must be retained until at least 10 years after the last  
21 approval. If the responsible investigator retires, relocates, or for other reasons  
22 withdraws from the responsibility of keeping the study records, custody must be  
23 transferred to a person who will accept the responsibility.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

#### 45 **Withdrawal and discontinuation**

46  
47 Patient participation may be terminated prior to completing the Visit 4 for any of  
48 the following reason:  
49

- 50 - The patient withdraws her informed consent for whatever reason.
  - 51 - Non cooperative patient, lack of compliance.
- 52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 - Occurrence of a transient disease, which might distort the results of this  
4 study or represents a contraindication.  
5  
6  
7

8  
9 Premature termination of the study must be agreed upon by the principal  
10 investigator and must be documented. Reasons for premature termination  
11 include: inadequate recruitment of patients, a protocol violation was identified  
12 or developed during the study, failure of responsible investigator to comply with  
13 the protocol or GCP guidelines.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Planned analysis**

26  
27  
28 The statistical analysis will be conducted by the Clinical Trial Unit Basel.  
29 Detailed methodology for summaries and statistical analyses of the data  
30 collected in this study will be documented in a statistical analysis plan. The  
31 statistical analysis plan will be finalized before database closure and will be  
32 under version control at the Clinical Trial Unit Basel. The Full Analysis Set will  
33 consist of all included women for whom serum hepcidin level in the first  
34 trimester (11-14 weeks of gestation) is available. Demographics and baseline  
35 characteristics will be reported for obese and non-obese woman separately and  
36 taken together.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

### 56 **Primary analysis**

1  
2  
3 The primary objective is to compare the primary endpoint between obese and  
4 non-obese pregnant women. If data are approximatively normally distributed, a  
5 two-sample t-test will be applied. Otherwise, data transformation (e.g. log), the  
6 use of a generalized linear model (GLM) with a Poisson error distribution, or the  
7 use of a non-parametric Wilcoxon two-sample rank test will be considered.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Secondary analyses**

21  
22  
23 Secondary endpoints measured in the first trimester (secondary objective 1) will  
24 be compared between obese and non-obese pregnant women as described for the  
25 primary endpoint. The course of the secondary endpoints during pregnancy  
26 (secondary objective 2) will be compared between obese and non-obese  
27 pregnant women using a random slope / random intercept linear mixed effects  
28 models for each endpoint. The model will include the respective secondary  
29 endpoint as dependent variable, study group (obese vs. non-obese), gestation  
30 week (continuous) and the interaction between study group and gestation week  
31 as fixed effects, and woman (patient ID) as random effect with random slope  
32 and random intercept. In case of an obvious non-linear time course, time will be  
33 included as categorical variable (time point: first, second and third trimester and  
34 delivery) instead, and a random intercept model will be applied (thus no random  
35 slope).  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The correlations between secondary endpoints measured during the course of  
4 pregnancy (secondary objective 3) will be described by means of scatterplots  
5 and Spearman's rank correlation coefficient for each trimester and at delivery  
6 separately. Adverse maternal outcome and adverse neonatal outcome will be  
7 analysed for an association with the listed secondary endpoints in the first  
8 trimester using logistic regression (secondary objectives 4 and 5). As a first step,  
9 univariate models will be fit. Each model will include the respective binary  
10 endpoint as dependent variable, and one of the secondary endpoints measured in  
11 the first trimester as explanatory variable. In order to test for a combined effect  
12 of the secondary endpoints, in a second step, multivariable logistic regression  
13 models will be fit. A forward model selection approach will be applied, based on  
14 Akaike's information criterion (AIC). Starting with the "null model" - the  
15 simplest model, including no explanatory variable - single predictor variables  
16 (i.e. secondary endpoints) will repeatedly be added if and as far as AIC can be  
17 decreased. This will result in a final model that includes the set of variables that  
18 (together) best describe the outcome. (A forward model selection approach is  
19 chosen, due to the relatively large number of predictors of interest in comparison  
20 to the expected number of events.) For each statistical model, odds ratios will be  
21 presented for each explanatory variable with 95% confidence intervals and p-  
22 values. Further, the frequency of each composite will be given for obese and  
23 non-obese women.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Interim analysis

The estimation of the variance (or the distribution in general) of hepcidin levels is crucial for determining the sample size of the study, but hepcidin levels observed in the study may deviate considerably from our assumptions. We will therefore re-estimate the sample size as soon as hepcidin levels of the first trimester of 80 % of the initially estimated number of women (i.e. 136 out of 169) will be available. We will re-estimate the variance  $\sigma^2$  obese and  $\sigma^2$  non-obese in a blinded manner – only the hepcidin levels of the third trimester will be available to the statistician performing the interim analysis. The overall variance  $\sigma^2$  will be estimated (one-sample variance estimator), assuming  $\sigma^2 = \sigma^2$  obese =  $\sigma^2$  non-obese. Since no hypothesis test is performed, no p-value adjustment to control type I error is needed. Using the re-estimated standard deviation, the sample size  $N'$  will be re-estimated as before. If there should be clear evidence against a normal distribution of hepcidin levels (based on visual inspection of quantile-quantile plots), a t-test based on transformed data or a non-parametric Wilcoxon two-sample rank test will be used. The sample size will be increased in order to include  $N'$  evaluable patients whenever  $N' > N$ , preserving a power of 80 %. A sample size reduction or early stopping of the study will not be considered.

## Deviations from the original statistical plan

1  
2  
3 If substantial deviations of the analysis as outlined in these sections are needed  
4  
5 for whatever reason, the protocol will be amended. All deviations of the analysis  
6  
7 from the protocol or from the detailed analysis plan will be listed and justified in  
8  
9 a separate section of the final statistical report.  
10  
11  
12  
13  
14  
15  
16

### 17 **Handling of missing data**

18  
19 Presumably, there may be reasons for drop outs confounded with the  
20  
21 measurements. For example, some composites of adverse maternal and neonatal  
22  
23 outcome will lead to a preterm end of pregnancy, which will result in missing  
24  
25 measurements after the first trimester. These data will be missing not at random.  
26  
27 It is important to keep these drop outs in the analysis set regarding secondary  
28  
29 objectives 4 and 5. In case there will be many such drop-outs (i.e. missing not at  
30  
31 random), inverse probability of censoring weights (IPCW) will be considered,  
32  
33 and a sensitivity analysis with a complete case analysis set will be performed.  
34  
35  
36  
37  
38  
39  
40  
41

42 Missing data and drop-outs will be handled using the method most appropriate,  
43  
44 based on an examination of missing values before data base closure. Details will  
45  
46 be specified in the statistical report and analysis plan. The number of missing  
47  
48 values in each endpoint and the number of drop-outs will be summarized for  
49  
50 obese and non-obese women.  
51  
52  
53  
54  
55  
56  
57  
58

### 59 **Confidentiality and Coding**

1  
2  
3 Project data will be handled with uttermost discretion and is only accessible to  
4  
5 authorized personnel who require the data to fulfil their duties within the scope  
6  
7 of the research project. On the CRFs and other project specific documents,  
8  
9 participants are only identified by a unique participant number. Biological  
10  
11 material in this project is not identified by participant name but by a unique  
12  
13 participant number.  
14  
15  
16  
17

18  
19  
20 Biological material and health-related personal data will be coded. The coding  
21  
22 key will be located by the investigator and the members of her research team.  
23  
24 Access to this key will only have the investigator and the members of her  
25  
26 research team. Biological material is appropriately stored in a restricted area  
27  
28 only accessible to authorized personnel. Data generation, transmission, storage  
29  
30 and analysis of health related personal data and the storage of biological samples  
31  
32 within this project will follow strictly the current Swiss legal requirement for  
33  
34 data protection and will be performed according to the HRO Art. 5. Health  
35  
36 related personal data captured during this project and biological samples from  
37  
38 participants are strictly confidential and disclosure to third parties is prohibited;  
39  
40 coding will safeguard participants` confidentiality. Only the investigator and  
41  
42 members of her research team will have access to project plan, dataset, statistical  
43  
44 code etc. during and after the research project.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

### 59 **Retention and destruction of study data and biological material**

60

1  
2  
3 The investigator/institution will take measures to prevent accidental or  
4 premature destruction of these documents. Essential documents must be retained  
5  
6 until at least 10 years after the last approval. After measurement, biological  
7  
8 material will be destroyed at the in University Hospital of Basel, Department of  
9  
10  
11  
12  
13  
14 Laboratory Medicine.  
15

### 16 17 **Data sharing**

18  
19  
20 After publication of the study individual anonymous participant data including  
21  
22 variable keys will be available upon request by the corresponding author.  
23  
24  
25 Researchers may request data to repeat the analyses or use the data for  
26  
27  
28 secondary analyses (e.g. systematic review and meta-analysis).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Obesity is a low-grade chronic inflammatory condition linked to the overexpression of hepcidin and secondarily to iron homeostasis. Increased hepcidin in obese pregnant women without gestational diabetes mellitus was shown in previous studies.<sup>7, 9, 22, 23</sup> Obesity-related inflammation may induce hepcidin biosynthesis with a consequent reduction of iron supply.<sup>7, 24</sup> Anelli et al. showed lower haemoglobin concentration in obese pregnant women.<sup>22</sup> Interestingly, anaemia was not related to the increase in hepcidin, while this was positively associated with maternal BMI.<sup>22</sup>

Few studies have evaluated the influence of obesity on hepcidin and iron status during pregnancy, but their results are inconclusive. Whereas increased hepcidin in obese pregnant women was shown in previous studies,<sup>7, 9, 22, 23</sup> it has not been confirmed in another studies.<sup>25, 26</sup> Due to previous data, we expect to observe an increase in the serum hepcidin in obese pregnant women, consequentially increased soluble transferrin receptors as a marker for iron deficiency in cells and a lower level of haemoglobin because of iron deficiency.

There is unclear which obese pregnant women develop during pregnancy complications such as gestational diabetes, pregnancy induced hypertension, pre-eclampsia, intrahepatic cholestasis, intrauterine growth restriction etc. Increased serum hepcidin could indicate the increased risk of adverse maternal and neonatal outcome. Chen et al showed that increased hepcidin restrains the



1  
2  
3 iron release from the cells by affecting the expression of ferroportin, which  
4 probably associates with the development of diabetes complication.<sup>14</sup> High  
5  
6 ferritin in the first trimester was also associated with GDM.<sup>27, 28</sup>  
7  
8

9  
10  
11 The role of hepcidin in pre-eclamptic pregnant women is unclear. Hepcidin  
12 levels in the first half of pregnancy were found significantly higher in women  
13 who subsequently developed pre-eclampsia compared to mothers having a  
14 physiological pregnancy until term.<sup>30</sup> Reason could be due to an inflammatory  
15 condition that characterizes the pre-eclamptic syndrome long before the  
16 symptoms onset. The identification of women at elevated risk of preeclampsia  
17 may be sufficiently early to allow the prophylactic use of low-dose aspirin,  
18 which has been demonstrated to reduce the prevalence of preeclampsia when  
19 started before 16 weeks' gestation. For the first time to our knowledge, a  
20 prospective study will be performed in order to verify the association between  
21 hepcidin in obese women and pregnancy outcome such intrahepatic cholestasis  
22 of pregnancy, haemorrhage, intrauterine growth restriction etc.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 In conclusion, we will contribute new information regarding the effects of  
45 obesity on iron and hepcidin levels. Our findings will improve the understanding  
46 of hepcidin and iron metabolism in obese pregnant women and provide direction  
47 for maternal and foetal complications. We expect that the usefulness of hepcidin  
48 in the early detection of women with an increased risk of developing maternal  
49 and foetal complications could be confirmed by our prospective cohort study.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 This may conduce to establish new promising biomarkers and possible life care

1  
2  
3 intervention, aimed at reducing the obesity-related risks in pregnancy. Our  
4  
5 findings could be of clinical and public health importance since serum hepcidin  
6  
7 as a biological marker for pregnancy risk can improve the prenatal care and  
8  
9 optimize peripartal and postpartal management in the future.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Ethics and dissemination

This study received ethical approval from the ethics committee in Basel (Project-ID: 2017-02322). It was registered under <http://www.ClinicalTrials.gov> (NCT03792464) on 7 January 2019. All members of the research team are aware of the guidelines for good clinical practice for obtaining consent. The principal investigator must ensure that all ethical and legal requirements have been met before the first patient is enrolled in the study. This protocol is to be followed exactly. To alter the protocol, amendments must be written, receive approval from the appropriate personnel, and receive Ethics Committee approval prior to implementation. Administrative changes (not affecting the patient benefit/risk ratio) may be made without the need for a formal amendment.

Before each patient is admitted to the study, signed informed consent will be obtained from the patient according to the regulatory and legal requirements. This consent form must be dated and retained by the investigator as part of the study records. The informed consent should be in accordance with the current revision of the Declaration of Helsinki, current International Conference on Harmonization (ICH) and Good Clinical Practice (GCP) guidelines.

The physicians and study coordinators must explain to potential participants the aims, methods, reasonably anticipated benefits of this study. Patients will be informed that they are free not to participate in the study and that they may withdraw consent to participate at any time. They will be told that competent

1  
2  
3 authorities may examine their records and authorized persons but that personal  
4  
5 information will be treated as strictly confidential and will not be publicly  
6  
7 available. Patients must be given the opportunity to ask questions. After this  
8  
9 explanation and before entry into the study, consent should be appropriately  
10  
11 recorded by means of the patient`s dated signature.  
12  
13  
14  
15  
16

17 If a protocol amendment is required, the informed consent form may need to be  
18  
19 revised to reflect the changes to the protocol. If the consent form is revised, it  
20  
21 must be approved and signed by all patients subsequently enrolled in the study.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. *BMJ* 2017 Feb 8; 356:j1. doi: 10.1136/bmj.j1. Review.
2. Flynn AC, Begum S, White SL, et al. Relationships between maternal obesity and maternal and neonatal iron status. *Nutrients* 2018 Jul 30; 10(8). pii: E1000. doi: 10.3390/nu10081000.
3. van Santen S, Kroot JJ, Zijderveld G, et al. The iron regulatory hormone hepcidin is decreased in pregnancy: a prospective longitudinal study. *Clin Chem Lab Med* 2013; 51(7):1395-401.
4. Hedengran KK, Nelson D, Andersen MR. Hepcidin levels are low during pregnancy and increase around delivery in women without iron deficiency - a prospective cohort study. *J Matern Fetal Neonatal Med* 2016; 29(9):1506-8.
5. Kulik-Rechberger B, Kosciesza A, Szponar E, Domsud J. Hepcidin and iron status in pregnant women and full-term newborns in first days of life. *Ginekol Pol* 2016; 87(4):288-92.
6. Simavli S, Derbent AU, Uysal S, Turhan NÖ. Hepcidin, iron status, and inflammation variables among healthy pregnant women in the Turkish population. *J Matern Fetal Neonatal Med* 2014; 27(1):75-9.

- 1  
2  
3 7. Garcia-Valdes L, Campoy C, Hayes H, et al. The impact of maternal  
4 obesity on iron status, placental transferrin receptor expression and  
5 hepcidin expression in human pregnancy. *Int J Obes (Lond)* 2015;  
6 39(4):571-8.  
7
- 8  
9 8. Nazif HK, El-Shaheed AA, El-Shamy KA, et al. Study of serum hepcidin  
10 as a potential mediator of the disrupted iron metabolism in obese  
11 adolescents. *Int J Health Sci (Qassim)* 2015; 9(2):172-8.  
12
- 13  
14 9. Dao MC, Sen S, Iyer C, et al. Obesity during pregnancy and fetal iron  
15 status: is Heparin the link? *J Perinatol* 2013; 33:177-81.  
16
- 17  
18 10. Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of  
19 hepcidin in severe obesity is independent from diabetes and NASH.  
20 *Gastroenterology* 2006; 131:788-796.  
21
- 22  
23 11. Schulze KJ, Christian P, Ruczinski I, et al. Heparin and iron status  
24 among pregnant women in Bangladesh. *Asia Pac J Clin Nutr* 2008;  
25 17(3):451-56.  
26
- 27  
28 12. Finkenstedt A, Wildschwendter A, Brasse-Lagnel CG, et al. Heparin is  
29 correlated to soluble hemojuvelin but not to increased GDF15 during  
30 pregnancy. *Blood Cells Mol Dis* 2012; 48:233-37.  
31
- 32  
33 13. Chelchowska M, Swiatek E, Ambroszkiewicz J, et al. [Concentrations of  
34 pro-hepcidin in serum of pregnant women and in umbilical cord blood].  
35 *Ginekol Pol* 2008; 79(11):754-7.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 14.Chen Y, Yin HQ, Liu HL, et al. Hcpidin and iron metabolism in non-  
4  
5 diabetic obese and type 2 diabetic rats. *J Huazhong Univ Sci Technolog*  
6  
7  
8  
9  
10  
11 15.Pihan-Le Bars F, Bonnet F, Loréal O, et al. Indicators of iron status are  
12  
13 correlated with adiponectin expression in adipose tissue of patients with  
14  
15 morbid obesity. *Diabetes Metab* 2016; 42:105-11.  
16  
17  
18  
19 16.Cepeda-Lopez AC, Melse-Boonstra A, Zimmermann MB, Herter-Aeberli  
20  
21 I. In overweight and obese women, dietary iron absorption is reduced and  
22  
23 the enhancement of iron absorption by ascorbic acid is one-half that in  
24  
25 normal-weight women. *Am J Clin Nutr* 2015; 102:1389-97.  
26  
27  
28  
29 17.Yanoff LB, Mentie CM, Denkinger B, et al. Inflammation and iron  
30  
31 deficiency in the hypoferremia of obesity. *Int J Obes (Lond)* 2007;  
32  
33 31:1412-1419.  
34  
35  
36  
37 18. The American College of Obstetricians and Gynecologists. Hypertension  
38  
39 in Pregnancy. *Task Force on Hypertension in pregnancy* 2013.  
40  
41  
42  
43 19.World Health Organization. Iron Deficiency Anaemia. Assessment,  
44  
45 Prevention, and Control. *A guide for programme managers* 2001.  
46  
47  
48  
49 20.World Health Organization. Neonatal and perinatal mortality country,  
50  
51 regional and global estimates. *Country, Regional and Global Estimates*  
52  
53 2006.  
54  
55  
56  
57 21.UNICEF, WHO, The World Bank. Levels and trends in child mortality.  
58  
59  
60 *Report* 2014.

- 1  
2  
3 22. Anelli GM, Cardellicchio M, Novielli C, et al. Mitochondrial content and  
4 hepcidin are increased in obese pregnant mothers. *J Matern Fetal*  
5  
6 *Neonatal Med* 2018; 18:2388-2395.  
7  
8  
9  
10  
11 23. Cepeda-López AC, Aeberli I, Melse Boonstra A, et al. Does obesity  
12 increase risk for iron deficiency? A review of the literature and the  
13 potential mechanisms. *Int J Vitam Nutr Res* 2010; 80:263-70.  
14  
15  
16  
17  
18 24. Rehu M, Punnonen K, Ostland V, et al. Maternal serum hepcidin is low at  
19 term and independent of cord blood iron status. *Eur J Haematol* 2010;  
20 85(4):345-52.  
21  
22  
23  
24  
25 25. Cao C, Pressman EK, Cooper EM, et al. Pre-pregnancy body mass index  
26 and gestational weight gain have no negative impact on maternal or  
27 neonatal iron status. *Reprod Sci* 2016; 23:613-22.  
28  
29  
30  
31  
32 26. Jones AD, Zhao G, Jiang Y., et al. Maternal obesity during pregnancy is  
33 negatively associated with maternal and neonatal iron status. *Eur J Clin*  
34 *Nutr* 2016; 70(8):918-24.  
35  
36  
37  
38  
39 27. Rawal S, Hinkle SN, Bao W, et al. A longitudinal study of iron status  
40 during pregnancy and the risk of gestational diabetes: finding from a  
41 prospective, multiracial cohort. *Diabetologia* 2017; 60(2):249-57.  
42  
43  
44  
45  
46 28. Bowers KA, Olsen SF, Bao W, et al. Plasma concentrations of ferritin in  
47 early pregnancy are associated with risk of gestational diabetes mellitus in  
48 women in the Danish National Birth Cohort. *J Nutr* 2016; 146(9):1756-  
49 61.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 29. Cardaropoli S, Todros T, Nuzzo AM, et al. Maternal serum levels and  
4 placental expression of hepcidin in preeclampsia. *Pregnancy Hypertens.*  
5  
6 2018; 11:47-53.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Contributors** GAB is the principal investigator who designed the study and  
4  
5 drafted the article. DV is in charge with the Statistical analysis. IH reviewed and  
6  
7 edited the manuscript. All authors read and approved the final manuscript.  
8  
9

10  
11  
12 **Funding** This study is financial supported by the «Gottfried und Julia  
13  
14 Bangerter-Rhyner Stiftung» und “Freiwillige akademische Gesellschaft.”  
15  
16

17  
18 **Competing interests** None.  
19

20  
21 **Patient consent** Obtained.  
22

23  
24 **Ethics approval** The study was approved by the Ethics Committee of Basel  
25  
26 (Protocol ID: 2017-02322).  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. **Time and Event Schedule**

<b>Visits</b>	<b>Enrolment</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>
<b>Gestational weeks</b>	<b>6-10</b>	<b>11-14</b>	<b>24-28</b>	<b>32-36</b>	<b>Delivery</b>
Screen for eligibility Inclusion/exclusion criteria	X				
Written informed consent		X			
Demographic data		X			
Maternal age		X			
Gestational age		X	X	X	X
Gravidity		X			
Parity		X			
Blood pressure		X	X	X	X
Smoking status		X	X	X	X
Weight (kg)		X	X	X	X
Weight gain (kg)			X	X	X
BMI (kg/m <sup>2</sup> )		X	X	X	X
Medication		X	X	X	X
Blood examination:					
Haemogram		X	X	X	X
CRP		X	X	X	X
Serum hepcidin		X	X	X	X
Serum ferritin		X	X	X	X
Transferrin receptors		X	X	X	X
Maternal and neonatal outcome					X

# BMJ Open

## Serum hepcidin and iron status parameters in pregnant women and the association with adverse maternal and foetal outcome: a study protocol for a prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032280.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Aug-2019
Complete List of Authors:	Amstad Bencaiova, Gabriela; University Hospital Basel, Department of Obstetrics; Vogt, Deborah; University of Basel, Clinical Trial Unit Hoesli, Irene; University Hospital, University Basel, Obstetrics
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Diabetes and endocrinology, Haematology (incl blood transfusion), Nutrition and metabolism
Keywords:	hepcidin, pregnancy, BMI, pregnancy outcome

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Serum hepcidin and iron status parameters in pregnant**  
5  
6  
7  
8  
9 **women and the association with adverse maternal and**  
10  
11  
12  
13  
14 **foetal outcome: a study protocol for a prospective cohort**  
15  
16  
17  
18  
19 **study**  
20  
21  
22  
23  
24

25 **G Amstad Bencaiova, D R Vogt, I Hoesli**  
26  
27

28  
29  
30 Department of Obstetrics and Antenatal Care, University Hospital Basel,  
31  
32

33  
34 University Basel, Switzerland  
35  
36

37  
38  
39 Clinical Trial Unit, Department of Clinical Research, University Hospital  
40  
41

42  
43 Basel and University of Basel  
44  
45

46  
47  
48 **Corresponding author: Gabriela Amstad Bencaiova, MD**  
49  
50

51  
52  
53 Department of Obstetrics and Antenatal Care,  
54

55  
56  
57 University Hospital of Basel  
58  
59  
60

1  
2  
3 Spitalstrasse 21  
4  
5  
6  
7

8 CH-4031 Basel  
9  
10  
11  
12

13 Switzerland  
14  
15  
16  
17

18 Email: gabriela.amstad@usb.ch  
19  
20  
21  
22

23 Phone +41 61 556 59 22  
24  
25  
26  
27

28 Fax +41 61 265 9198  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Hepcidin production is normally upregulated by iron stores, and in obesity has been shown to be overexpressed and correlated with low iron status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of ferroportin, which probably associates with the development of diabetes complication. Firstly, we investigate the difference of serum hepcidin and iron parameters between obese and non-obese pregnant women; secondly, we examine the correlation between serum hepcidin and adverse maternal and neonatal outcomes in pregnant women.

**Methods and analysis:** This is a mono-centre, prospective cohort study with a study (obese) and a control group (non-obese women). 188 singleton pregnancies will be recruited in the first trimester. Thereof, we expect 75 with a BMI  $\geq 30$  kg/m<sup>2</sup> and 113 with a BMI 18.5 -- 30 kg/m<sup>2</sup>.

1  
2  
3  
4 Serum hepcidin, iron and haematological parameters will be measured at  
5  
6  
7 11-14, 24-28, 32-36 weeks of gestation and at time of delivery. Blood  
8  
9  
10  
11 pressure, weight, BMI and smoking status will be examined at all visits.  
12  
13

14  
15 We will assess the composite endpoints adverse maternal outcome  
16  
17 (including pre-eclampsia, gestational hypertension, gestational diabetes,  
18  
19 haemorrhage, placenta abruption), and adverse neonatal outcome  
20  
21 (preterm birth, intrauterine growth restriction, preterm premature rupture  
22  
23 of membranes, Apgar score <7 at 5 minutes, still birth, neonatal death).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Recruitment has started in April 2019.  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 **Ethics and dissemination:** This study received ethical approval from the  
47  
48 ethics committee in Basel. The results of the study will be published in a  
49  
50 peer-reviewed journal, and presented at national scientific conferences. It  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 was registered under <http://www.ClinicalTrials.gov> (NCT03792464) on 7 January  
5  
6  
7  
8 2019.

9  
10  
11  
12 **Trial registration number: NCT03792464.**

### 13 14 15 16 17 **Strengths and limitations of this study**

18  
19  
20  
21  
22 For the first time to our knowledge, a prospective study will be performed  
23  
24  
25  
26 in order to verify the association between hepcidin and pregnancy  
27  
28  
29  
30 outcome.

31  
32  
33  
34  
35 At the time of planning this study, no data on hepcidin levels of obese  
36  
37  
38  
39 pregnant women in the first trimester were available.

40  
41  
42  
43 A blinded sample size re-estimation could be performed provided hepcidin  
44  
45  
46  
47 levels deviate from our assumptions for sample size estimation.

48  
49  
50  
51 An important limitation of the study may be the size of the study population  
52  
53  
54  
55 for the analysis of secondary outcomes since we only powered for our  
56  
57  
58  
59 primary outcome.  
60

1  
2  
3  
4 Our findings could generate the first signs of the potential association  
5  
6  
7  
8 between hepcidin and adverse pregnancy outcomes and initiate other  
9  
10  
11  
12 powered studies.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Introduction

Obesity is the most common problem in obstetrics that affects both the mother and her offspring.<sup>1</sup> Obesity causes short term and long term problems for the mother, such as increasing her risk of gestational diabetes (GDM) and pre-eclampsia during pregnancy and further increases the risk of developing the metabolic syndrome in later life. The offspring have an increased risk of obstetric morbidity and mortality and, consistent with the developmental origins of health and disease, a long term risk of childhood obesity and metabolic dysfunction.<sup>1</sup>

Obesity is also associated with an increased risk of iron deficiency, attributable to adiposity-related inflammatory mediators on iron regulatory pathways.<sup>2</sup> The pro-inflammatory cytokine interleukin-6 (IL-6), frequently elevated in obesity, has been shown to induce expression of hepcidin<sup>2</sup>, a

1  
2  
3  
4 negative regulator of intestinal iron absorption and macrophage iron efflux.  
5  
6

7  
8 Normal foetal growth and development is dependent upon maternal iron  
9  
10  
11 sufficiency during pregnancy. Pregnant women have an increased  
12  
13  
14  
15 requirement of iron to support foetoplacental development, expansion of  
16  
17  
18  
19 maternal red blood cell mass, and to compensate for intrapartum blood  
20  
21  
22  
23 loss; to meet this need, absorption of dietary iron is enhanced concomitant  
24  
25  
26  
27 with increased utilization of existing iron stores. During a healthy  
28  
29  
30  
31 pregnancy, hepcidin is reduced, enabling iron transfer to the fetus.<sup>3-6</sup>  
32  
33  
34

35  
36 Obesity in pregnancy may lead to hepcidin excess and decreased iron  
37  
38  
39 transfer to the fetus.<sup>7-9</sup> Low iron stores are reported to be more common  
40  
41  
42  
43 in obese pregnant women.<sup>10</sup> The correlation between serum ferritin and  
44  
45  
46  
47 hepcidin has been shown in previous studies.<sup>3,5,8,11,12</sup> Although in other  
48  
49  
50  
51 studies, no correlation between serum hepcidin and iron status has been  
52  
53  
54  
55 found.<sup>4,6,13</sup> To strengthen the link between the poor iron status of obesity  
56  
57  
58  
59 and hepcidin, there is the interesting observation that hepcidin is  
60

1  
2  
3  
4 expressed not only in the liver but also in adipose tissue and that mRNA  
5  
6  
7  
8 expression is increased in adipose tissue of obese pregnant patients.<sup>7</sup> The  
9  
10  
11 increased hepcidin may restrain the iron release from the cells by affecting  
12  
13  
14  
15 the expression of ferroportin, which probably associates with the  
16  
17  
18  
19 development of diabetes complication.<sup>14</sup> Iron content appears to be  
20  
21  
22  
23 increased in the subcutaneous and visceral adipose tissue of obese  
24  
25  
26  
27 patients, and negatively correlated with adiponectin expression, which  
28  
29  
30  
31 could be contributing to insulin resistance and the metabolic complications  
32  
33  
34  
35  
36 of obesity.<sup>15</sup>

37  
38  
39  
40 There are few studies examining the influence of maternal obesity on  
41  
42  
43  
44 maternal iron status, with some indicating that iron status may be  
45  
46  
47  
48 compromised (<sup>7-9,16</sup>), and others reporting no impact.<sup>17</sup> However dietary or  
49  
50  
51  
52 iron supplementation was not assessed and might be responsible for  
53  
54  
55  
56 divergent results. There is no study evaluating the difference of serum  
57  
58  
59  
60

1  
2  
3  
4 hepcidin and ferritin between obese and non-obese pregnant women  
5  
6  
7  
8 longitudinally during pregnancy as well as the association between these  
9  
10  
11  
12 parameters and adverse pregnancy outcome.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Methods and analysis

### Primary objective

The primary objective is serum hepcidin level (ng/ml) measured at 11-14 weeks of gestation.

### Secondary objectives

1. To compare iron status parameters, haemogram and CRP measured in the first trimester between obese and non-obese pregnant women.
2. To describe the course of serum hepcidin, iron status parameters, haemogram, CRP, weight and BMI during pregnancy and to compare them between obese and non-obese pregnant women.
3. To describe the correlations between serum hepcidin, iron status parameters, haemogram, CRP, weight and BMI in each trimester and at delivery.

1  
2  
3  
4 4. To investigate whether adverse pregnancy outcome is associated with  
5  
6  
7  
8 serum hepcidin and iron status in the first trimester and during total  
9  
10  
11 pregnancy.  
12

13  
14  
15  
16 5. To investigate whether adverse neonatal outcome is associated with  
17  
18  
19  
20 serum hepcidin and iron status in the first trimester and during total  
21  
22  
23 pregnancy.  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 **Study design**

34  
35  
36  
37 This is a mono-centre, prospective cohort study with a study (obese) and  
38  
39  
40 a control group (non-obese women). This study protocol was developed  
41  
42  
43 on the basis of Standard Protocol Items: Recommendations for  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000



## Study settings

The study will be conducted at the University Hospital of Basel, Department of Obstetrics and Antenatal Care with 2800 deliveries/year.

The study has started in April 2019. We estimate to recruit all patients within 18 months. A total of N=188 healthy pregnant women (expected 75=40% with BMI  $\geq 30$  kg/m<sup>2</sup>) will be recruited in the first trimester in our outpatients' department. Considering a drop-out rate of 10% we will have a total of 169 evaluable women.

## Eligible criteria

### Inclusion criteria

- Age  $\geq 18$  years
- Singleton pregnancy
- BMI  $\geq 18.5$  kg/m<sup>2</sup>

- 1  
2  
3  
4 • Gestational age at recruitment: 11-14 of gestational weeks  
5  
6  
7  
8 • Written informed consent.  
9  
10

### 11 Exclusion criteria

12

- 13  
14  
15  
16 • Foetal genetic, chromosomal or intervention-requiring morphological  
17  
18 abnormalities  
19  
20  
21  
22  
23  
24  
25 • Chronic disease of heart, liver, kidney, cardiovascular system,  
26  
27 gastrointestinal tract, neurologic, autoimmune, haematological  
28  
29 disorders and psychiatric disorders or known infection like hepatitis  
30  
31  
32  
33  
34  
35  
36  
37 or HIV  
38  
39  
40  
41  
42 • The inability to read and/or understand the participant's information  
43  
44  
45  
46 sheet.  
47  
48  
49  
50  
51  
52  
53

### 54 Assessment of primary outcome

55  
56  
57  
58  
59  
60

1  
2  
3  
4 The serum hepcidin will be investigated at 11-14, 24-28, 32-36 weeks of  
5  
6  
7  
8 gestation and at labour. Blood samples are collected by venepuncture.  
9

10  
11 The measurement of serum hepcidin will be conducted at the University  
12  
13  
14  
15  
16 Hospital of Basel, Department of Biomedicine. Serum hepcidin will be  
17  
18  
19  
20 measured with an ELISA. No additional visit is necessary besides the  
21  
22  
23  
24 standard routine antenatal care visits.  
25  
26  
27  
28  
29  
30  
31

### 32 **Assessment of secondary outcomes**

33  
34  
35  
36  
37 Serum iron parameters (serum ferritin and soluble transferrin receptors)  
38  
39  
40  
41 will be measured at 11-14, 24-28, 32-36 weeks of gestation and at labour.  
42  
43  
44

45 Iron parameters will be determined using routine laboratory methodology.  
46  
47

48  
49 Blood samples will be collected by venepuncture. All blood measurements  
50  
51  
52  
53 will be conducted at the University Hospital of Basel, Department of  
54  
55  
56  
57 Laboratory Medicine and Department of Biomedicine.  
58  
59  
60

1  
2  
3  
4 The following maternal outcome will be investigated: pre-eclampsia  
5  
6  
7  
8 defined according to the «Report of the American College of  
9  
10  
11 Obstetricians and Gynecologists` Task Force on Hypertension in  
12  
13  
14  
15 pregnancy»<sup>18</sup>, pregnancy induced hypertension<sup>18</sup>, infection in pregnancy  
16  
17  
18 (urinary tract infection, vaginal infection, chorioamnionitis etc.), anaemia  
19  
20  
21  
22  
23 and iron deficiency in pregnancy according to the World Health  
24  
25  
26  
27 Organization (WHO) with ferritin cut-off of 15 µg/l<sup>19</sup>, cholestasis of  
28  
29  
30  
31 pregnancy, gestational diabetes mellitus according to the results of an  
32  
33  
34  
35 oral 75g glucose test, mode of delivery, abnormal placentation, placental  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 infections, anaemia and placenta abruption are defined as adverse  
4  
5  
6  
7 maternal outcome.  
8  
9

10  
11 The following neonatal outcome should be investigated: gestational age  
12  
13  
14  
15 at birth, birth weight, Apgar score, pH levels, preterm delivery < 37 weeks  
16  
17  
18 of gestation, preterm premature rupture of membranes (PPROM),  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

10  
11 The following neonatal outcome should be investigated: gestational age  
12  
13  
14  
15 at birth, birth weight, Apgar score, pH levels, preterm delivery < 37 weeks  
16  
17  
18 of gestation, preterm premature rupture of membranes (PPROM),  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

WHO<sup>20</sup>, neonatal death defined according to UNICEF and WHO<sup>21</sup>,  
admissions to the neonatal unit care (NICU). Preterm birth, IUGR,  
PPROM, macrosomia, Apgar score < 7 at 5, still birth and neonatal death  
are defined as adverse neonatal outcome.

## Participant time line and study procedures

1  
2  
3  
4 All healthy pregnant patients with regular care at our outpatients'  
5  
6  
7 department are counselled and asked at six –10 weeks of gestation to  
8  
9  
10  
11 participate. At 10+0 to 13+6 weeks of gestation, all women have to  
12  
13  
14  
15 undergo a first trimester ultrasound scan which is standard care. The  
16  
17  
18  
19 ultrasound scan is used to confirm gestational  
20  
21  
22  
23  
24 age, diagnose any major foetal abnormalities. All pregnant women that  
25  
26  
27  
28 meet in- /exclusion criteria will be recruited in the first trimester in the  
29  
30  
31  
32 framework of regular pregnancy visit through physicians, midwives and  
33  
34  
35  
36 study coordinators. Serum hepcidin, iron and haematological parameters  
37  
38  
39  
40 will be measured at 11-14, 24-28, 32-36 weeks of gestation and at labour.  
41  
42  
43  
44 The blood pressure, weight, weight gain, body mass index (BMI) and  
45  
46  
47  
48 smoking status will be examined at all visits as a standard of care. Time  
49  
50  
51  
52 and event schedule provides an overview about the schedule of  
53  
54  
55  
56 observations and assessments (Table 1).  
57  
58  
59  
60

Table 1. Time and Event Schedule

Visits	Enrolment	1	2	3	4
<b>Gestational weeks</b>	<b>6-10</b>	<b>11-14</b>	<b>24-28</b>	<b>32-36</b>	<b>Delivery</b>
Screen for eligibility Inclusion/exclusion criteria	X				
Written informed consent		X			
Demographic data		X			
Maternal age		X			
Gestational age		X	X	X	X
Gravidity		X			
Parity		X			
Blood pressure		X	X	X	X
Smoking status		X	X	X	X
Weight (kg)		X	X	X	X
Weight gain (kg)			X	X	X
BMI (kg/m <sup>2</sup> )		X	X	X	X

Medication		X	X	X	X
Blood examination:					
Haemogram		X	X	X	X
CRP		X	X	X	X
Serum hepcidin		X	X	X	X
Serum ferritin		X	X	X	X
Transferrin receptors		X	X	X	X
Maternal and neonatal outcome					X

## Haematological parameters

This is a routine examination on the visit 1, 2, 3 and 4 haemoglobin (Hb), red blood cell count (RBC), haematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), percentage of microcytic erythrocytes (MRC), hypochromic red blood cells (HRC) and reticulocyte haemoglobin content (CHr) are measured using a haematology analyser. Mean corpuscular haemoglobin is automatically calculated from Hb and RBC.



## Serum ferritin, CRP, hepcidin and soluble transferrin receptors

There are additional examinations on the visit 1, 2, 3 and 4. Ferritin is assessed by chemiluminescence immunoassay and CRP is assessed by immunoturbidimetry. Soluble transferrin receptors and serum hepcidin are measured with an ELISA.

## Recording of medications

All medications being continued by a patient on enrolment and all medications given in addition must be documented on the Case report form (CRF) and in the patient's medical records.

## Sample size

1  
2  
3  
4 Sample size is estimated so that a difference between obese and non-  
5  
6  
7  
8 obese pregnant women regarding the primary endpoint- serum hepcidin  
9  
10  
11 level in the first trimester- can be shown with 80% power, at a significance  
12  
13  
14  
15 level  $\alpha = 5\%$ .

16  
17  
18  
19  
20 Sample size estimation is based on the following assumptions:  
21  
22

- 23  
24 • The proportion of obese women is expected to be 40%.
- 25  
26  
27  
28  
29 • We assume hepcidin levels to be normally distributed with equal variance  
30  
31  
32 for obese and non-obese women.
- 33  
34  
35  
36  
37 • Based on results reported in Dao et al.<sup>9</sup> for obese women in the second  
38  
39  
40  
41 trimester, and assuming these are similar in the first trimester, we assume  
42  
43  
44  
45 a mean hepcidin level of 13.5 ng/ml in the first trimester and a standard  
46  
47  
48  
49 deviation of  $\sigma = 9.0$  ng/ml. Dao et al.<sup>9</sup> report a mean difference of 8.0 ng/ml  
50  
51  
52  
53 between obese and non-obese women, while Garcia-Valdes et al.<sup>7</sup> report  
54  
55  
56  
57 a mean difference of approximately 5.0 ng/ml. Here, we aim to show a  
58  
59  
60

1  
2  
3 difference of 4.0 ng/ml, thus we assume  $\mu = 17.5$  ng/ml in non-obese  
4  
5  
6  
7 women. A clinical significance of the difference of 4.0 ng/ml will be  
8  
9  
10  
11 monitored examining the correlation between serum hepcidin and adverse  
12  
13  
14  
15 pregnancy outcomes.  
16  
17

18  
19  
20 Sample size was calculated using a re-sampling procedure. Each sample  
21  
22  
23 size ( $n_i=1, \dots, 71 = 20, \dots, 300$ ) was evaluated first determining the number  
24  
25  
26 of obese women (expected 40%, c.f. above) by sampling 999 times from  
27  
28  
29 a binomial distribution with  $n = n_i$  and probability  $p = 0.4$ . Then, 999 times  
30  
31  
32  $n_i$  observations, were sampled from the above described distributions for  
33  
34  
35 non-obese women and obese women, respectively. The difference in each  
36  
37  
38 sample between obese and non-obese women was then tested using a  
39  
40  
41 two- samples t-test. The null hypothesis was rejected when the difference  
42  
43  
44 was statistically significant ( $p < 0.05$ ). Sample size was set to ensure a  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 significant result in at least 80 % of the cases (power:  $1 - \beta = 0.8$ ), at a  
5  
6  
7  
8 significance level  $\alpha = 5\%$ .  
9

10  
11  
12 Supposing to show a hepcidin difference of 4.0 ng/ml, a total of 188  
13  
14  
15  
16 women should be recruited in order to have a total of 169 evaluable  
17  
18  
19  
20 women, considering a drop-out rate of 10%. A sample size re-estimation  
21  
22  
23  
24 is planned as soon as hepcidin levels of the first trimester of 80% of the  
25  
26  
27  
28 initially estimated number of women (i.e. 136 out of 169) will be available  
29  
30  
31  
32 (c.f. Interim Analysis). P-values resulting from secondary analyses will not  
33  
34  
35  
36 be interpreted as confirmative but will be used to identify hypotheses worth  
37  
38  
39  
40 of further investigation.  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **Data collection**

51  
52  
53 The study data recorded in the CRF will be transferred to a corresponding  
54  
55  
56  
57  
58 electronic CRF (e-CRF) by a designated person. The data will be extracted  
59  
60

1  
2  
3 from clinical records by study nurses and study coordinators. The principal  
4  
5  
6  
7 investigator will be responsible for assuring that the data entered into the  
8  
9  
10  
11 e-CRF is complete, accurate, and that the entry and updates are  
12  
13  
14  
15 performed in timely manner. All information recorded in the e-CRFs will be  
16  
17  
18  
19 traceable to the source documents in the patient's file and in the date  
20  
21  
22  
23  
24 source files.  
25  
26  
27

28 The e-CRF will be implemented by the Data management group at the  
29  
30  
31  
32 Clinical Trial Unit Basel using the electronic data capture (EDC) software  
33  
34  
35  
36 SecuTrial. The EDC system runs on a server maintained by the IT-  
37  
38  
39  
40 department of the University Hospital Basel.  
41  
42  
43  
44

45 Internal data management will be conducted. The data-review and data-  
46  
47  
48 handling documents, to be developed during the initiation phase of the  
49  
50  
51  
52 study, will include specifications for consistency and plausibility checks on  
53  
54  
55  
56  
57 data and will also include data handling rules for obvious data errors.  
58  
59  
60

1  
2  
3  
4 In compliance with the International Council on Harmonization and GCP  
5  
6  
7  
8 guidelines the investigator/institution will maintain all source documents  
9  
10  
11 that support the data collected from each patient, and all documents as  
12  
13  
14  
15 specified in Essential Documents for the Conduct of a study and as  
16  
17  
18 specified by the applicable regulatory requirements. The  
19  
20  
21  
22  
23  
24 investigator/institution will take measures to prevent accidental or  
25  
26  
27  
28 premature destruction of these documents. Essential documents must be  
29  
30  
31  
32 retained until at least 10 years after the last approval. If the responsible  
33  
34  
35  
36 investigator retires, relocates, or for other reasons withdraws from the  
37  
38  
39  
40 responsibility of keeping the study records, custody must be transferred to  
41  
42  
43  
44 a person who will accept the responsibility.  
45  
46  
47  
48  
49  
50  
51  
52

### 53 **Withdrawal and discontinuation**

54  
55  
56  
57  
58  
59  
60

1  
2  
3 Patient participation may be terminated prior to completing the Visit 4 for

4  
5  
6  
7 any of the following reason:

- 8  
9  
10  
11  
12 - The patient withdraws her informed consent for whatever reason.  
13  
14  
15  
16 - Non cooperative patient, lack of compliance.  
17  
18  
19  
20  
21 - Occurrence of a transient disease, which might distort the results of  
22  
23  
24  
25 this study or represents a contraindication.  
26  
27  
28

29  
30 Premature termination of the study must be agreed upon by the principal  
31  
32  
33 investigator and must be documented. Reasons for premature termination  
34  
35  
36  
37 include: inadequate recruitment of patients, a protocol violation was  
38  
39  
40  
41 identified or developed during the study, failure of responsible investigator  
42  
43  
44  
45 to comply with the protocol or GCP guidelines.  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **Planned analysis**

55  
56  
57  
58  
59  
60

1  
2  
3  
4 The statistical analysis will be conducted by the Clinical Trial Unit Basel.  
5  
6

7  
8 Detailed methodology for summaries and statistical analyses of the data  
9

10  
11 collected in this study will be documented in a statistical analysis plan. The  
12

13  
14  
15 statistical analysis plan will be finalized before database closure and will  
16

17  
18  
19 be under version control at the Clinical Trial Unit Basel. The Full Analysis  
20

21  
22  
23 Set will consist of all included women for whom serum hepcidin level in the  
24

25  
26  
27 first trimester (11-14 weeks of gestation) is available. Demographics and  
28

29  
30  
31 baseline characteristics will be reported for obese and non-obese woman  
32

33  
34  
35 separately and taken together.  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **Primary analysis**

46  
47  
48  
49 The primary objective is to compare the primary endpoint between obese  
50

51  
52  
53 and non-obese pregnant women. If data are approximatively normally  
54

55  
56  
57 distributed, a two-sample t-test will be applied. Otherwise, data  
58  
59  
60



1  
2  
3  
4 transformation (e.g. log), the use of a generalized linear model (GLM) with  
5  
6  
7  
8 a Poisson error distribution, or the use of a non-parametric Wilcoxon two-  
9  
10  
11  
12 sample rank test will be considered.  
13  
14  
15  
16  
17  
18  
19

## 20 **Secondary analyses**

21  
22  
23  
24 Secondary endpoints measured in the first trimester (secondary objective  
25  
26  
27  
28 1) will be compared between obese and non-obese pregnant women as  
29  
30  
31  
32 described for the primary endpoint. The course of the secondary endpoints  
33  
34  
35  
36 during pregnancy (secondary objective 2) will be compared between  
37  
38  
39  
40  
41 obese and non-obese pregnant women using a random slope / random  
42  
43  
44  
45 intercept linear mixed effects models for each endpoint. The model will  
46  
47  
48  
49 include the respective secondary endpoint as dependent variable, study  
50  
51  
52  
53 group (obese vs. non-obese), gestation week (continuous) and the  
54  
55  
56  
57 interaction between study group and gestation week as fixed effects, and  
58  
59  
60

1  
2  
3  
4 woman (patient ID) as random effect with random slope and random  
5  
6  
7  
8 intercept. In case of an obvious non-linear time course, time will be  
9  
10  
11 included as categorical variable (time point: first, second and third  
12  
13  
14  
15 trimester and delivery) instead, and a random intercept model will be  
16  
17  
18  
19 applied (thus no random slope).  
20  
21  
22  
23

24 The correlations between secondary endpoints measured during the  
25  
26  
27 course of pregnancy (secondary objective 3) will be described by means  
28  
29  
30  
31 of scatterplots and Spearman's rank correlation coefficient for each  
32  
33  
34  
35 trimester and at delivery separately. Adverse maternal outcome and  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3  
4 trimester as explanatory variable. In order to test for a combined effect of  
5  
6  
7  
8 the secondary endpoints, in a second step, multivariable logistic  
9  
10  
11 regression models will be fit. A forward model selection approach will be  
12  
13  
14  
15 applied, based on Akaike's information criterion (AIC). Starting with the  
16  
17  
18  
19 "null model" - the simplest model, including no explanatory variable - single  
20  
21  
22  
23 predictor variables (i.e. secondary endpoints) will repeatedly be added if  
24  
25  
26  
27  
28 and as far as AIC can be decreased. This will result in a final model that  
29  
30  
31  
32 includes the set of variables that (together) best describe the outcome. (A  
33  
34  
35  
36 forward model selection approach is chosen, due to the relatively large  
37  
38  
39  
40 number of predictors of interest in comparison to the expected number of  
41  
42  
43  
44 events.) For each statistical model, odds ratios will be presented for each  
45  
46  
47  
48 explanatory variable with 95% confidence intervals and p-values. Further,  
49  
50  
51  
52 the frequency of each composite will be given for obese and non-obese  
53  
54  
55  
56 women.  
57  
58  
59  
60

## Interim analysis

The estimation of the variance (or the distribution in general) of hepcidin levels is crucial for determining the sample size of the study, but hepcidin levels observed in the study may deviate considerably from our assumptions. We will therefore re-estimate the sample size as soon as hepcidin levels of the first trimester of 80 % of the initially estimated number of women (i.e. 136 out of 169) will be available. We will re-estimate the variance  $\sigma^2_{\text{obese}}$  and  $\sigma^2_{\text{non-obese}}$  in a blinded manner – only the hepcidin levels of the third trimester will be available to the statistician performing the interim analysis. The overall variance  $\sigma^2$  will be estimated (one-sample variance estimator), assuming  $\sigma^2 = \sigma^2_{\text{obese}} = \sigma^2_{\text{non-obese}}$ . Since no hypothesis test is performed, no p-value adjustment to control type I error is needed. Using the re-estimated standard deviation,

1  
2  
3 the sample size  $N'$  will be re-estimated as before. If there should be clear  
4  
5  
6  
7 evidence against a normal distribution of hepcidin levels (based on visual  
8  
9  
10  
11 inspection of quantile-quantile plots), a t-test based on transformed data  
12  
13  
14  
15 or a non-parametric Wilcoxon two-sample rank test will be used. The  
16  
17  
18  
19 sample size will be increased in order to include  $N'$  evaluable patients  
20  
21  
22  
23  
24 whenever  $N' > N$ , preserving a power of 80 %. A sample size reduction or  
25  
26  
27  
28 early stopping of the study will not be considered.  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Deviations from the original statistical plan**

38  
39  
40  
41 If substantial deviations of the analysis as outlined in these sections are  
42  
43  
44  
45 needed for whatever reason, the protocol will be amended. All deviations  
46  
47  
48  
49 of the analysis from the protocol or from the detailed analysis plan will be  
50  
51  
52  
53 listed and justified in a separate section of the final statistical report.  
54  
55  
56  
57  
58  
59  
60

## Handling of missing data

Presumably, there may be reasons for drop outs confounded with the measurements. For example, some composites of adverse maternal and neonatal outcome will lead to a preterm end of pregnancy, which will result in missing measurements after the first trimester. These data will be missing not at random. It is important to keep these drop outs in the analysis set regarding secondary objectives 4 and 5. In case there will be many such drop-outs (i.e. missing not at random), inverse probability of censoring weights (IPCW) will be considered, and a sensitivity analysis with a complete case analysis set will be performed.

Missing data and drop-outs will be handled using the method most appropriate, based on an examination of missing values before data base closure. Details will be specified in the statistical report and analysis plan.

1  
2  
3  
4 The number of missing values in each endpoint and the number of drop-  
5  
6  
7  
8 outs will be summarized for obese and non-obese women.  
9

## 16 Confidentiality and Coding

20  
21 Project data will be handled with uttermost discretion and is only  
22  
23  
24  
25 accessible to authorized personnel who require the data to fulfil their duties  
26  
27  
28  
29 within the scope of the research project. On the CRFs and other project  
30  
31  
32  
33 specific documents, participants are only identified by a unique participant  
34  
35  
36  
37 number. Biological material in this project is not identified by participant  
38  
39  
40  
41 name but by a unique participant number.  
42  
43  
44  
45

46 Biological material and health-related personal data will be coded. The  
47  
48  
49  
50 coding key will be located by the investigator and the members of her  
51  
52  
53  
54 research team. Access to this key will only have the investigator and the  
55  
56  
57  
58 members of her research team. Biological material is appropriately stored  
59  
60

1  
2  
3  
4 in a restricted area only accessible to authorized personnel. Data  
5  
6  
7  
8 generation, transmission, storage and analysis of health related personal  
9  
10  
11 data and the storage of biological samples within this project will follow  
12  
13  
14  
15 strictly the current Swiss legal requirement for data protection and will be  
16  
17  
18  
19 performed according to the HRO Art. 5. Health related personal data  
20  
21  
22  
23 captured during this project and biological samples from participants are  
24  
25  
26  
27 strictly confidential and disclosure to third parties is prohibited; coding will  
28  
29  
30  
31 safeguard participants` confidentiality. Only the investigator and members  
32  
33  
34  
35 of her research team will have access to project plan, dataset, statistical  
36  
37  
38  
39 code etc. during and after the research project.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **Retention and destruction of study data and biological material**

51  
52  
53  
54 The investigator/institution will take measures to prevent accidental or  
55  
56  
57  
58 premature destruction of these documents. Essential documents must be  
59  
60



1  
2  
3 retained until at least 10 years after the last approval. After measurement,  
4  
5  
6  
7 biological material will be destroyed at the in University Hospital of Basel,  
8  
9  
10  
11 Department of Laboratory Medicine.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

## 22 **Data sharing**

23  
24  
25  
26 After publication of the study individual anonymous participant data  
27  
28  
29  
30 including variable keys will be available upon request by the corresponding  
31  
32  
33  
34 author. Researchers may request data to repeat the analyses or use the  
35  
36  
37  
38 data for secondary analyses (e.g. systematic review and meta-analysis).  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **Patient and public involvement**

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Patients and the public were neither involved in developing the hypothesis,  
5  
6  
7  
8 the specific aims or the research question, nor were they involved in  
9  
10  
11  
12 developing plan for design or implementation of the study.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Discussion

Obesity is a low-grade chronic inflammatory condition linked to the overexpression of hepcidin and secondarily to iron homeostasis.

Increased hepcidin in obese pregnant women without gestational diabetes mellitus was shown in previous studies.<sup>7, 9, 22, 23</sup> Obesity-related inflammation may induce hepcidin biosynthesis with a consequent reduction of iron supply.<sup>7, 24</sup> Anelli et al. showed lower haemoglobin concentration in obese pregnant women.<sup>22</sup> Interestingly, anaemia was not related to the increase in hepcidin, while this was positively associated with maternal BMI.<sup>22</sup>

Few studies have evaluated the influence of obesity on hepcidin and iron status during pregnancy, but their results are inconclusive. Whereas increased hepcidin in obese pregnant women was shown in previous studies,<sup>7, 9, 22, 23</sup> it has not been confirmed in another studies.<sup>25, 26</sup> Due to

1  
2  
3  
4 previous data, we expect to observe an increase in the serum hepcidin in  
5  
6  
7  
8 obese pregnant women, consequentially increased soluble transferrin  
9  
10  
11  
12 receptors as a marker for iron deficiency in cells and a lower level of  
13  
14  
15  
16 haemoglobin because of iron deficiency.  
17

18  
19  
20 It is unclear which obese pregnant women develop during pregnancy  
21  
22  
23 complications such as gestational diabetes, pregnancy induced  
24  
25  
26  
27  
28 hypertension, pre-eclampsia, intrahepatic cholestasis, intrauterine growth  
29  
30  
31  
32 restriction etc. Increased serum hepcidin could indicate the increased risk  
33  
34  
35  
36 of adverse maternal and neonatal outcome. Chen et al showed that  
37  
38  
39  
40 increased hepcidin restrains the iron release from the cells by affecting the  
41  
42  
43  
44 expression of ferroportin, which probably associates with the development  
45  
46  
47  
48 of diabetes complication.<sup>14</sup> High ferritin in the first trimester was also  
49  
50  
51  
52 associated with GDM.<sup>27, 28</sup>  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The role of hepcidin in pre-eclamptic pregnant women is unclear. Hepcidin  
5  
6  
7  
8 levels in the first half of pregnancy were found significantly higher in  
9  
10  
11  
12 women who subsequently developed pre-eclampsia compared to mothers  
13  
14  
15  
16 having a physiological pregnancy until term.<sup>29</sup> Reason could be due to an  
17  
18  
19  
20 inflammatory condition that characterizes the pre-eclamptic syndrome  
21  
22  
23  
24 long before the symptoms onset. The identification of women at elevated  
25  
26  
27  
28 risk of pre-eclampsia may be sufficiently early to allow the prophylactic use  
29  
30  
31  
32 of low-dose aspirin, which has been demonstrated to reduce the  
33  
34  
35  
36 prevalence of pre-eclampsia when started before 16 weeks` gestation.  
37  
38  
39

40 For the first time to our knowledge, a prospective study will be performed  
41  
42  
43  
44 in order to verify the potential association between hepcidin in obese  
45  
46  
47  
48 women and pregnancy outcome such intrahepatic cholestasis of  
49  
50  
51  
52 pregnancy, haemorrhage, intrauterine growth restriction etc. However, an  
53  
54  
55  
56 important limitation of this study may be the size of the study population.  
57  
58  
59  
60

1  
2  
3 We only powered for our primary outcome, not for secondary analyses.  
4  
5  
6

7  
8 On the other hand, our findings could generate the first signs of the  
9  
10  
11 potential association between hepcidin and adverse pregnancy outcomes.  
12  
13  
14

15  
16 In conclusion, we will contribute new information regarding the effects of  
17  
18  
19 obesity on iron and hepcidin levels. Our findings will improve the  
20  
21  
22 understanding of hepcidin and iron metabolism in obese pregnant women  
23  
24  
25 and provide direction for maternal and foetal complications. Our results  
26  
27  
28 could initiate planning and conducting of powered studies to verify the  
29  
30  
31 potential association between hepcidin and adverse pregnancy outcomes.  
32  
33  
34  
35  
36  
37  
38

39  
40 Acknowledgement of this hypothesis may conduce to establish new  
41  
42  
43 promising biomarkers and possible life care intervention, aimed at  
44  
45  
46 reducing the obesity-related risks in pregnancy.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Ethics and dissemination

This study received ethical approval from the ethics committee in Basel (Project-ID: 2017-02322). It was registered under <http://www.ClinicalTrials.gov> (NCT03792464) on 7 January 2019. All members of the research team are aware of the guidelines for good clinical practice for obtaining consent. The principal investigator must ensure that all ethical and legal requirements have been met before the first patient is enrolled in the study. This protocol is to be followed exactly. To alter the protocol, amendments must be written, receive approval from the appropriate personnel, and receive Ethics Committee approval prior to implementation. Administrative changes (not affecting the patient benefit/risk ratio) may be made without the need for a formal amendment.

Before each patient is admitted to the study, signed informed consent will be obtained from the patient according to the regulatory and legal

1  
2  
3 requirements. This consent form must be dated and retained by the  
4  
5  
6  
7 investigator as part of the study records. The informed consent should be  
8  
9  
10  
11 in accordance with the current revision of the Declaration of Helsinki,  
12  
13  
14  
15 current International Conference on Harmonization (ICH) and Good  
16  
17  
18  
19 Clinical Practice (GCP) guidelines.  
20  
21  
22

23  
24 The physicians and study coordinators must explain to potential  
25  
26  
27  
28 participants the aims, methods, reasonably anticipated benefits of this  
29  
30  
31  
32 study. Patients will be informed that they are free not to participate in the  
33  
34  
35  
36 study and that they may withdraw consent to participate at any time. They  
37  
38  
39  
40 will be told that competent authorities may examine their records and  
41  
42  
43  
44 authorized persons but that personal information will be treated as strictly  
45  
46  
47  
48 confidential and will not be publicly available. Patients must be given the  
49  
50  
51  
52 opportunity to ask questions. After this explanation and before entry into  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 the study, consent should be appropriately recorded by means of the  
5  
6  
7  
8 patient`s dated signature.  
9

10  
11  
12 If a protocol amendment is required, the informed consent form may need  
13  
14  
15  
16 to be revised to reflect the changes to the protocol. If the consent form is  
17  
18  
19  
20 revised, it must be approved and signed by all patients subsequently  
21  
22  
23  
24 enrolled in the study.  
25  
26  
27  
28

29 The findings of this study will be published in a peer-reviewed journal, and  
30  
31  
32  
33 presented at national scientific conferences, to disseminate the results to  
34  
35  
36  
37 academic and health professional audiences, and made available to  
38  
39  
40  
41 participants and to a wider public on our website at the time of publication.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. *BMJ* 2017 Feb 8; 356:j1. doi: 10.1136/bmj.j1. Review.
2. Flynn AC, Begum S, White SL, et al. Relationships between maternal obesity and maternal and neonatal iron status. *Nutrients* 2018 Jul 30; 10(8). pii: E1000. doi: 10.3390/nu10081000.
3. van Santen S, Kroot JJ, Zijderveld G, et al. The iron regulatory hormone hepcidin is decreased in pregnancy: a prospective longitudinal study. *Clin Chem Lab Med* 2013; 51(7):1395-401.
4. Hedengran KK, Nelson D, Andersen MR. Hepcidin levels are low during pregnancy and increase around delivery in women without iron deficiency - a prospective cohort study. *J Matern Fetal Neonatal Med* 2016; 29(9):1506-8.

- 1  
2  
3  
4 5. Kulik-Rechberger B, Kosciesza A, Szponar E, Domsud J. Heparin  
5  
6  
7 and iron status in pregnant women and full-term newborns in first  
8  
9  
10  
11 days of life. *Ginekol Pol* 2016; 87(4):288-92.  
12  
13
- 14  
15  
16 6. Simavli S, Derbent AU, Uysal S, Turhan NÖ. Heparin, iron status,  
17  
18  
19 and inflammation variables among healthy pregnant women in the  
20  
21  
22  
23 Turkish population. *J Matern Fetal Neonatal Med* 2014; 27(1):75-9.  
24  
25
- 26  
27  
28 7. Garcia-Valdes L, Campoy C, Hayes H, et al. The impact of maternal  
29  
30  
31  
32 obesity on iron status, placental transferrin receptor expression and  
33  
34  
35  
36 heparin expression in human pregnancy. *Int J Obes (Lond)* 2015;  
37  
38  
39  
40 39(4):571-8.  
41  
42  
43
- 44  
45  
46 8. Nazif HK, El-Shaheed AA, El-Shamy KA, et al. Study of serum  
47  
48  
49  
50  
51  
52  
53 heparin as a potential mediator of the disrupted iron metabolism in  
54  
55  
56  
57  
58  
59  
60 obese adolescents. *Int J Health Sci (Qassim)* 2015; 9(2):172-8.
9. Dao MC, Sen S, Iyer C, et al. Obesity during pregnancy and fetal  
iron status: is Heparin the link? *J Perinatol* 2013; 33:177-81.

- 1  
2  
3  
4 10. Bekri S, Gual P, Anty R, et al. Increased adipose tissue  
5  
6  
7 expression of hepcidin in severe obesity is independent from  
8  
9  
10  
11 diabetes and NASH. *Gastroenterology* 2006; 131:788-796.  
12  
13  
14  
15  
16 11. Schulze KJ, Christian P, Ruczinski I, et al. Hepcidin and iron  
17  
18  
19 status among pregnant women in Bangladesh. *Asia Pac J Clin Nutr*  
20  
21  
22  
23 2008; 17(3):451-56.  
24  
25  
26  
27  
28 12. Finkenstedt A, Wildschwendter A, Brasse-Lagnel CG, et al.  
29  
30  
31 Hepcidin is correlated to soluble hemojuvelin but not to increased  
32  
33  
34  
35  
36  
37  
38  
39 GDF15 during pregnancy. *Blood Cells Mol Dis* 2012; 48:233-37.  
40  
41  
42  
43  
44 13. Chelchowska M, Swiatek E, Ambroszkiewicz J, et al.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
60 [Concentrations of pro-hepcidin in serum of pregnant women and in  
umbilical cord blood]. *Ginekol Pol* 2008; 79(11):754-7.  
  
14. Chen Y, Yin HQ, Liu HL, et al. Hepcidin and iron metabolism  
in non-diabetic obese and type 2 diabetic rats. *J Huazhong Univ Sci  
Technolog Med Sci* 2015; 35:851-857.

- 1  
2  
3  
4 15. Pihan-Le Bars F, Bonnet F, Loréal O, et al. Indicators of iron  
5  
6  
7 status are correlated with adiponectin expression in adipose tissue  
8  
9  
10  
11 of patients with morbid obesity. *Diabetes Metab* 2016; 42:105-11.  
12  
13  
14  
15  
16 16. Cepeda-Lopez AC, Melse-Boonstra A, Zimmermann MB,  
17  
18 Herter-Aeberli I. In overweight and obese women, dietary iron  
19  
20 absorption is reduced and the enhancement of iron absorption by  
21  
22 ascorbic acid is one-half that in normal-weight women. *Am J Clin*  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 *Nutr* 2015; 102:1389-97.  
33  
34  
35  
36 17. Yanoff LB, Mentie CM, Denkinger B, et al. Inflammation and  
37  
38 iron deficiency in the hypoferrremia of obesity. *Int J Obes (Lond)*  
39  
40  
41  
42  
43  
44  
45 2007; 31:1412-1419.  
46  
47  
48 18. The American College of Obstetricians and Gynecologists.  
49  
50  
51  
52 Hypertension in Pregnancy. *Task Force on Hypertension in*  
53  
54  
55  
56  
57 *pregnancy* 2013.  
58  
59  
60

- 1  
2  
3  
4 19. World Health Organization. Iron Deficiency Anaemia.  
5  
6  
7 Assessment, Prevention, and Control. *A guide for programme*  
8  
9  
10  
11 *managers* 2001.  
12  
13  
14  
15  
16 20. World Health Organization. Neonatal and perinatal mortality  
17  
18  
19 country, regional and global estimates. *Country, Regional and*  
20  
21  
22 *Global Estimates* 2006.  
23  
24  
25  
26  
27  
28 21. UNICEF, WHO, The World Bank. Levels and trends in child  
29  
30  
31 mortality. *Report* 2014.  
32  
33  
34  
35  
36 22. Anelli GM, Cardelicchio M, Novielli C, et al. Mitochondrial  
37  
38  
39 content and hepcidin are increased in obese pregnant mothers. *J*  
40  
41  
42 *Matern Fetal Neonatal Med* 2018; 18:2388-2395.  
43  
44  
45  
46  
47  
48 23. Cepeda-López AC, Aeberli I, Melse Boonstra A, et al. Does  
49  
50  
51 obesity increase risk for iron deficiency? A review of the literature  
52  
53  
54 and the potential mechanisms. *Int J Vitam Nutr Res* 2010; 80:263-  
55  
56  
57  
58  
59  
60 70.

- 1  
2  
3  
4 24. Rehu M, Punnonen K, Ostland V, et al. Maternal serum  
5  
6  
7 hepcidin is low at term and independent of cord blood iron status.  
8  
9  
10  
11 *Eur J Haematol* 2010; 85(4):345-52.  
12  
13  
14  
15  
16 25. Cao C, Pressman EK, Cooper EM, et al. Pre-pregnancy body  
17  
18  
19 mass index and gestational weight gain have no negative impact on  
20  
21  
22  
23  
24  
25  
26  
27  
28 26. Jones AD, Zhao G, Jiang Y., et al. Maternal obesity during  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 27. Rawal S, Hinkle SN, Bao W, et al. A longitudinal study of iron  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57 28. Bowers KA, Olsen SF, Bao W, et al. Plasma concentrations of  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 diabetes mellitus in women in the Danish National Birth Cohort. *J*

4  
5  
6  
7  
8 *Nutr* 2016; 146(9):1756-61.

9  
10  
11 29. Cardaropoli S, Todros T, Nuzzo AM, et al. Maternal serum

12  
13  
14  
15 levels and placental expression of hepcidin in pre-eclampsia.

16  
17  
18  
19  
20 *Pregnancy Hypertens*. 2018; 11:47-53.



1  
2  
3  
4 **Contributors** GAB is the principal investigator who designed the study and  
5  
6  
7  
8 drafted the article. DV is in charge with the Statistical analysis. IH reviewed  
9  
10  
11  
12 and edited the manuscript. All authors read and approved the final  
13  
14  
15  
16 manuscript.

17  
18  
19  
20 **Funding** This study is financial supported by the «Gottfried und Julia  
21  
22  
23  
24 Bangerter-Rhyner Stiftung» und “Freiwillige akademische Gesellschaft.”  
25  
26  
27  
28

29  
30 **Competing interests** None.  
31  
32

33  
34 **Patient consent** Obtained.  
35  
36  
37

38 **Ethics approval** The study was approved by the Ethics Committee of Basel  
39  
40  
41  
42 (Protocol ID: 2017-02322).  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5, 6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8, 9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9, 10, 11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11, 12, 13
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	13
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	17-19
		(b) Describe any methods used to examine subgroups and interactions	18
		(c) Explain how missing data were addressed	20
		(d) If applicable, explain how loss to follow-up was addressed	20
		(e) Describe any sensitivity analyses	19, 20
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	It is a study protocol
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	24
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	25
Generalisability	21	Discuss the generalisability (external validity) of the study results	26
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	34

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).